Ocular Hypertension Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Nicox, Qlaris Bio, TheratOcula, Ocular Therapeutix

September 20 05:50 2023
Ocular Hypertension Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Nicox, Qlaris Bio, TheratOcula, Ocular Therapeutix
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 70+ key pharma and biotech companies are working on 75+ pipeline drugs in the Ocular Hypertension therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Ocular Hypertension Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Ocular Hypertension Market. 

The Ocular Hypertension Pipeline report embraces in-depth commercial, regulatory, and Ocular Hypertension clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Ocular Hypertension drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Ocular Hypertension Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Ocular Hypertension treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Ocular Hypertension therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Ocular Hypertension companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Ocular Hypertension drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Ocular Hypertension therapeutic market.

Ocular Hypertension Therapeutics Landscape

Ocular hypertension (OHT) is defined by IOP higher than 21 mm Hg, a normal optic nerve head (ONH) appearance, and a normal visual field. OHT can progress to glaucoma and may require treatment. Risk factors such as family history, increased cup-to-disc ratio, or reduced central corneal thickness (CCT) are related to an elevated risk for glaucoma development.

Currently, the market has been categorized based on different classes of therapies available in the market for the treatment of OHT. These include prostaglandin analogs, beta-blockers, alpha-agonists, carbonic anhydrase inhibitors, sympathomimetic, and miotics.

The current market for OHT is squeezed by various generics like Travoprosta, Bimatoprosta, Maleato de timolol, Latanoprosta by EMS Pharmaceutical, brimonidine tartrat and timolol maleate combination eyedrop by Sandoz etc. which might impact the market scenario in future. In Spetember 2022, Omidenepag isopropyl, or DE-117, or EYBELIS, a topical ophthalmic solution, received approval in the US to treat elevated IOP in patients with glaucoma or OHT. It is a selective agonist for the prostanoid receptor, EP2, in contrast to the prostaglandin analogs (PGAs), a commonly prescribed class of medications that acts on an FP receptor. The product is already marketed in Japan as EYBELIS.

Several major pharma and biotech companies are developing therapies for Ocular Hypertension. Currently, Deerland Probiotics & Enzymes is leading the therapeutics market with its Ocular Hypertension drug candidates in the most advanced stage of clinical development.

Ocular Hypertension Companies Actively Working in the Therapeutic Market Include:

  • Nicox

  • Qlaris Bio

  • TheratOcular Biotek Co., Ltd.

  • Ocular Therapeutix

  • Whitecap Biosciences, LLC

  • JeniVision, Inc.

  • AbbVie

  • Santen

  • VivaVision Biotech

  • ONL Therapeutics

  • Skye Bioscience

  • MediPrint Ophthalmics

  • Sun Pharma Advanced Research Company

  • Ripple Therapeutics

  • Peregrine Ophthalmic

  • Laboratorios Sophia

  • Whitecap Biosciences

  • pH Pharma

  • Chong Kun Dang

  • Laboratoires Thea

And Many Others

Emerging and Marketed Ocular Hypertension Drugs Covered in the Report Include:

  • NCX-470: Nicox

  • QLS-101: Qlaris Bio

  • TO-O-1001: TheratOcular Biotek Co., Ltd.

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Ocular Hypertension Companies Working in the Market @ 


Analysis of Emerging Ocular Hypertension Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Ocular Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide

  • Peptide

  • Small molecule

Learn How the Ocular Hypertension Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Ocular Hypertension Treatment Patterns

4. Ocular Hypertension – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Ocular Hypertension Late Stage Products (Phase-III)

7. Ocular Hypertension Mid-Stage Products (Phase-II)

8. Ocular Hypertension Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Ocular Hypertension Discontinued Products

13. Ocular Hypertension Product Profiles

14. Major Ocular Hypertension Companies in the Market

15. Key Products in the Ocular Hypertension Therapeutics Segment

16. Dormant and Discontinued Products

17. Ocular Hypertension Unmet Needs

18. Ocular Hypertension Future Perspectives

19. Ocular Hypertension Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @




About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Seborrhoeic Dermatitis Market

“Seborrhoeic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Seborrhoeic Dermatitis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Seborrhoeic Dermatitis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/